Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions

Circulating tumor DNA (ctDNA) has emerged as a potential new biomarker with diagnostic, predictive, and prognostic applications for various solid tumor types. Before beginning large prospective clinical trials to prove the added value of utilizing ctDNA in clinical practice, it is essential to inves...

Descripción completa

Detalles Bibliográficos
Autores principales: van Dessel, Lisanne F., Beije, Nick, Helmijr, Jean C.A., Vitale, Silvia R., Kraan, Jaco, Look, Maxime P., de Wit, Ronald, Sleijfer, Stefan, Jansen, Maurice P.H.M., Martens, John W.M., Lolkema, Martijn P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527445/
https://www.ncbi.nlm.nih.gov/pubmed/28164427
http://dx.doi.org/10.1002/1878-0261.12037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527445/
https://www.ncbi.nlm.nih.gov/pubmed/28164427
http://dx.doi.org/10.1002/1878-0261.12037

Ejemplares similares